Role of Microbiome in the Realm of Immune Checkpoint Inhibitor Induced GI Complications in the Cancer Population (Phase I)

All Cancers
Yinghong Wang, MD
The University of Texas MD Anderson Cancer Center


Gastrointestinal (GI) complications due to immune checkpoint inhibitor (ICPI) therapy can be a severe side-effect that can be life-threatening for cancer patients. In 30-50% of cases, the standard therapy to treat these GI complication does not work. This trial is testing the effectiveness and safety of a fecal microbiota transplant (FMT) to treat GI complications. If proven to be safe and effective, FMT will be a groundbreaking milestone for the management of ICPI-related GI complications in cancer patients.